Evidence map›Paper›PMID 35750030›Full record

ArticleCell2022

Shigella "Osp"pression of innate immunity.

Skylar S Wright, Sivapriya Kailasan Vanaja

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Molecular Mechanisms ofInternational journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Skylar S WrightDepartment of Immunology, University of Connecticut Health School of Medicine 263 Farmington Ave., Farmington, CT 06030, USA.
Sivapriya Kailasan VanajaDepartment of Immunology, University of Connecticut Health School of Medicine 263 Farmington Ave., Farmington, CT 06030, USA. Electronic address: kailasanvanaja@uchc.edu.
UConn Health · US

Funding

Bacterial modulation of noncanonical inflammasomeR01AI132850 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KAILASAN VANAJA, SIVAPRIYA · 2018 to 2022
$2.0M
NIAID NIH HHS R01 AI132850
6 · The paper itself

Abstract

Interferons are potent antimicrobial effectors and thus an attractive target for pathogen interference. In this issue of Cell, Alphonse et al. reveal that the Shigella effectors OspC1 and OspC3 employ a surprising mechanism to block interferon signaling and attenuate antibacterial responses, thus securing their replicative niche.

Indexed as

Dysentery, BacillaryShigellaHost-Pathogen InteractionsHumansImmunity, InnateInterferonsInterferons

Identifiers

PMID35750030
OpenAlexW4283399977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.